Clemens Doppler

Techniplas is a global supplier of sophisticated plastic components and design-focused, multifunctional surfaces that are primarily for the automotive sector, as well as the industrial, consumer goods, medical and other markets. The company’s products follow industry trends like weight reduction and vehicle electrification, innovative operating concepts, high-quality surface finishes, and an increasing focus on convenience and safety. The Techniplas Group runs 30 sites worldwide with production, sales and / or technology hubs and employs just under 4,000 members of staff. The company serves customers and platforms around the world, focusing on technological expertise and collaboration with customers in the fields of design and engineering. Techniplas has long-term relationships with many of the world’s leading automotive and industrial OEMs.

Techniplas is a global supplier of sophisticated plastic components and design-focused, multifunctional surfaces that are primarily for the automotive sector, as well as the industrial, consumer goods, medical an other markets. For more information, please visit www.techniplas.com.

vasopharm is dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences.

KREATECH Diagnostics is a Molecular Diagnostics company focusing on the development and world-wide commercialization of innovative detection products. KREATECH’s product portfolio enables customers to detect genetic aberrations that may lead to cancer or other diseases. KREATECH offers the broadest commercial portfolio of DNA-FISH probes available in the industry: more than 450 REPEAT-FREE™ POSEIDON™ FISH probes. The REPEAT-FREE™ technology eliminates the use of Cot-1 or blocking DNA, providing less background and a brighter signal which are important features for FISH as a diagnostic and research tool. In addition, KREATECH has a portfolio for dedicated (microarray) labeling applications using its proprietary non-enzymatic Universal Linkage System (ULS™) labeling technology. KREATECH Diagnostics has commercial operations both in Europe and North America. For more information, please visit www.kreatech.com

Combinature Biopharm is a biotechnology company based out of Berlin, Berlin, Germany.

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-class dissociative steroid with novel mode of action, currently investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases. Santhera out-licensed rights to its first approved product, Raxone® (idebenone), outside North America and France for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For more information, please visit the Company's website at www.santhera.com

Santhera Pharmaceuticals (Schweiz) AG is a pharmaceuticals company based out of HAMMERSTRASSE 49, Liestal, Switzerland.

Micromet is a biopharmaceutical company focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's BiTE® antibody platform represents a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet's second BiTE antibody in clinical development is MT110, which targets the EpCAM. The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab (or MT201), a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of GM-CSF, which has potential applications in the treatment of inflammatory and autoimmune diseases, such as RA, psoriasis, or MS. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

As part of the Miltenyi Biotec GmbH group of companies Miltenyi Imaging GmbH, previously Sensovation AG, is a world leading partner for the design and production of unique Smart Imaging Solutions. Many years of experience and outstanding expertise in electronics, optics, and software development have made Miltenyi Imaging to an specialist of highly integrated Research and In-Vitro-Diagnostic devices, with a special focus on the rapidly growing field of multiplexed analysis and microscopy. Miltenyi Imaging is a certified manufacturer according to ISO 9001 and ISO 13485 and has established an efficient and certified quality management system. Compliance to the well-established, though continuously changing standards is the key for our customers to reach product-approval in the relevant markets. Our products conform to safety standards for our worldwide customers. Privacy Policy: https://www.miltenyi-imaging.com/privacy-policy

 Graffinity SCREENING SERVICES find small molecules that bind to proteins; a staring point for DISCOVERY of drugs or affinity ligands for protein purification. The staff are surface plasmon resonance experts advising on implementation of SPR. Higher throughput screens employ Graffinity microarrays - produced in-house – containing 9,216 immobilized small molecule ligands - with instruments not available elsewhere. Medium throughput tasks such as fragment library screens use microfluidic SPR Biacore® systems. DRUG DISCOVERY – screening platform for fragment & lead-like hits Small molecule drug discovery is served by Graffinity & its parent NovAliX through a unique integration of screening, medicinal chemistry & structural biology. The Graffinity library of 116,000 compounds has provided a starting point for chemical synthesis for over 90% of > 110 projects. A powerful reservoir of data concerning the binding properties of novel compounds has been created. The high sensitivity is particularly well suited for fragment based drug discovery, FBDD. Fragments (MW < 300) represent > 20% of the library. Recently great emphasis has been placed upon improving the quality of the library though the addition of compounds with favorable medicinal chemistry properties. The technology is equally applicable to target based discovery for agrochemicals, food flavors, fragrances & cosmetics. AFFINITY PURIFICATION: PROTEINS/biologics/enzymes - downstream processing A screening service discovers novel ligands for novel proteins. Development projects for antibody purification include: 1) a generic Fab binder, 2) HCP capture for reverse purification or polishing 3) an Fc binder with improved properties versus protein A. The probability of finding useful affinity is high and any purification systems will be novel, patentable. http://tiny.cc/SlideShareAffLig info@novalix-pharma.com

About Snom Technology GmbH Founded in 1997 and headquartered in Berlin Germany, Snom is a German multinational corporation and the world’s first and leading brand of professional and enterprise VoIP telephones. Snoms German engineering is globally renowned for robust, high-quality and feature-rich business telephones that are designed exclusively for the trained and certified professional IT and PBX installer. All of Snom’s products are universally compatible with leading PBX platforms operating under the SIP standard with over 4 million end-point installations globally. Snom products are sold through distributors to over 25,000 Snom Value Added Resellers across the world. For more information, please visit www.snom.com.

Techniplas is a global supplier of sophisticated plastic components and design-focused, multifunctional surfaces that are primarily for the automotive sector, as well as the industrial, consumer goods, medical and other markets. The company’s products follow industry trends like weight reduction and vehicle electrification, innovative operating concepts, high-quality surface finishes, and an increasing focus on convenience and safety. The Techniplas Group runs 30 sites worldwide with production, sales and / or technology hubs and employs just under 4,000 members of staff. The company serves customers and platforms around the world, focusing on technological expertise and collaboration with customers in the fields of design and engineering. Techniplas has long-term relationships with many of the world’s leading automotive and industrial OEMs.

Techniplas is a global supplier of sophisticated plastic components and design-focused, multifunctional surfaces that are primarily for the automotive sector, as well as the industrial, consumer goods, medical an other markets. For more information, please visit www.techniplas.com.